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Abstract
Objectives: Cognitive impairment remains frequent in HIV, despite combination antiretroviral therapy (cART). Leading
theories implicate peripheral monocyte HIV DNA reservoirs as a mechanism for spread of the virus to the brain. These
reservoirs remain present despite cART. The objective of this study was to determine if the level of HIV DNA in CD14+
enriched monocytes predicted cognitive impairment and brain injury.
Methods: We enrolled 61 cART-naı¨ve HIV-infected Thais in a prospective study and measured HIV DNA in CD14+ enriched
monocyte samples in a blinded fashion. We determined HAND diagnoses by consensus panel and all participants
underwent magnetic resonance spectroscopy (MRS) to measure markers of brain injury. Immune activation was measured
via cytokines in cerebrospinal fluid (CSF).
Results: The mean (SD) age was 35 (6.9) years, CD4 T-lymphocyte count was 236 (139) and log10 plasma HIV RNA was 4.8
(0.73). Twenty-eight of 61 met HAND criteria. The log10 CD14
+ HIV DNA was associated with HAND in unadjusted and
adjusted models (p = 0.001). There was a 14.5 increased odds ratio for HAND per 1 log-value of HIV DNA (10-fold increase in
copy number). Plasma CD14+ HIV DNA was associated with plasma and CSF neopterin (p= 0.023) and with MRS markers of
neuronal injury (lower N-acetyl aspartate) and glial dysfunction (higher myoinositol) in multiple brain regions.
Interpretation: Reservoir burden of HIV DNA in monocyte-enriched (CD14+) peripheral blood cells increases risk for HAND in
treatment-naı¨ve HIV+ subjects and is directly associated with CSF immune activation and both brain injury and glial
dysfunction by MRS.
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Introduction
Combination antiretroviral therapy (cART) suppresses plasma
HIV viral RNA to undetectable levels for most patients but fails to
universally eliminate reservoirs of HIV DNA. [1] The inability to
clear these reservoirs has emerged as the Achilles heel of HIV
eradication because withdrawal from treatment allows for rapid
new viral replication from these sources. Although sometimes
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assumed to be quiescent, the magnitude of the reservoir in
peripheral blood mononuclear cells (PBMC) has been linked to
HIV disease progression and mortality. [2,3] We hypothesize that
reservoirs within circulating monocytes contribute to cognitive
impairment and are likely to underlie continued brain injury.
Current neurological research has focused on the brain as a
protected site for HIV since not all antiretroviral medications have
shown high degrees of central nervous system (CNS) penetration
effectiveness (CPE). Our past work focused on the burden of HIV
DNA in PBMCs, and particularly those enriched for monocytes as
determined by expression of the CD14 cell surface marker. This
CD14+ HIV DNA reservoir is proportionally small compared to
that found in CD4+ T-lymphocytes; however, the overall CD14+
reservoir size has been linked to cognitive disorders among both
cART-treated and untreated patients in past cross-sectional post-
hoc correlative studies. [4,5,6,7] A recent study linked cART
regimens with higher effectiveness in monocytes to better overall
cognitive performance, a finding that was independent of CPE. [8]
Autopsy reports identify a monocyte/macrophage foundation to
cognitive impairment even among cART treated subjects, and
researchers have shown an association between soluble CD14 and
lysosomal proteins secreted by macrophages to cognitive impair-
ment and brain atrophy. [9,10,11,12,13] We now test the
hypothesis that CD14+ HIV DNA can identify subjects with
HAND prospectively in a blinded fashion, and evaluate the
mechanistic link to CNS injury by brain MRS and evaluation of
CSF immune activation.
Methods
Ethics Statement
All subjects provided written informed consent. The UCSF
Human Research Protection Program Committee on Human
Research provided approval of the consent form and study via the
Notification of Expedited Review Approval, expiry of 17 June
2013. The Institutional Review Board of the Faculty of Medicine,
Chulalongkorn University provided approval of the consent form
and study, stating ‘‘The Institutional Review Board of the Faculty
of Medicine, Chulalongkorn University, Bangkok, Thailand, has
approved the following study which is to be carried out in
compliance with the International guidelines for human research
protection as Declaration of Helsinki, the Belmont report, CIOMS
Guideline, and International Conference on Harmonization in
Good Clinical Practice (ICH-GCP),’’ expiry of 02 September
2013.
Patient Selection
SEARCH 011 (NCT00782808) was enrolled prospectively with
referrals from community clinicians for subjects that met Thai
Ministry of Public Health criteria for treatment initiation (CD4+
T-lymphocyte count ,350 cells/mm3 or symptomatic disease).
[14] All were screened for PBMC HIV DNA levels to ensure a full
range of HIV DNA in the final sample. Using a central
randomization center where clinical staff were blinded to these
levels, we aimed to enroll 30 cases with greater than and 30 cases
with less than 1000 copies of HIV DNA per 106 PBMCs. We used
PBMC rather than CD14+ cellular HIV DNA for screening
because logistical challenges precluded CD14+ cell separation in
real time, and because the two measures were highly correlated in
our preliminary studies. We further stratified by age of greater or
less than 35 years to minimize clustering by age, a factor that could
impact cognition.
Clinicians remained blinded to all HIV DNA levels and
laboratory technicians were blinded to clinical data, including
cognitive information, for the duration of the study. Subjects were
excluded for head injury, current illicit drug use or a positive urine
toxicology test at either the screening or entry visit, acute
concurrent illness, pre-existing neurologic or psychiatric condi-
tions, or learning disability. We enrolled 63 subjects, but excluded
two at entry when opportunistic CNS infections were discovered
(toxoplasmosis and tuberculosis).
Cognitive Characterization
Trained nurse-psychometrists administered neuropsychological
tests from a battery developed for international use by the World
Health Organization (WHO) and modified slightly for feasibility,
as previously described. [15,16] The battery includes the WHO
Auditory Verbal Learning Task (WHO AVLT) for learning
efficiency, immediate and delayed recall; the Brief Visual Memory
Task-Revised (BVMT-R); Color Trails 1 and 2; Escala de
Inteligencia de Wechsler para Adultos (EIWA) Digit Symbol and
Block Design Tasks; the Grooved Pegboard for both hands; Finger
Tapping for both hands; Timed Gait; two verbal fluency tasks (first
name and animals); and the Trail Making Test A. The study
neurologist conducted a standardized examination developed by
the AIDS Clinical Trials Group (ACTG). Nurses and physicians
independently interviewed subjects and, when possible, inter-
viewed proxy informants to identify functional limitations due to
cognitive impairment. Individual neuropsychological test raw
scores were compared to age- and education-stratified Thai
normative data to generate standardized z-scores ((subject score –
normative score)/normative standard deviation) and were com-
bined to provide a global composite z-score (NPZglobal) as the
arithmetic mean of all standardized scores per subject. [17].
Clinical diagnoses of cognitive impairment were assigned in a
consensus conference that included the principle investigator (VV),
a U.S. HIV neurologist (DBC), and a U.S. HIV neuropsychologist
(RP) using the 2007 (‘‘Frascati’’) diagnostic criteria as a guide. [18]
Given the limitations of the brief one-hour neuropsychological
battery, clinical acumen was required to judge whether the
abnormalities were mild or moderate in nature and to conclude if
there was sufficient evidence for cognitive abnormalities beyond
normal test variation. We allowed for slight departures from the
2007 nosology when consensus was achieved to define the
following: cognitively normal (NL): testing performance deemed
to be within expectations for age and educational attainment;
asymptomatic neurocognitive impairment (ANI): performance
deemed to be worse than expected with normal test variation
(typically involving at least two domains) but without evidence of
functional impairment; mild neurocognitive disorder (MND):
moderately abnormal performance (typically 1 to 2 SD below
normative data) in two cognitive domains and with evidence of
functional impairment; and HIV-associated dementia (HAD):
severe impairment (typically worse than 22 SD) in two cognitive
domains with clear evidence of functional impairment. [18]
Consensus conference members were blinded to HIV DNA levels.
Standard laboratory evaluations included a complete blood cell
count with T-lymphocyte subsets, HIV RNA, liver profiles, blood
chemistries, syphilis serology, vitamin B12 level, thyroid function
tests, and hepatitis serology. Lumbar puncture was optional and
obtained on 43 subjects. CSF and plasma viral loads were
measured using the Amplicor HIV-1 Monitor Assay (Roche
Molecular System, Inc., Branchburg, NJ).
Cell Separation
PBMCs were isolated using Ficoll HistopaqueH (Sigma, St Louis
MO) density gradient centrifugation and washed three times with
RPMI1640 culture media (Life Technologies, Grand Island NY)
HIV DNA Reservoir Size and Risk for HAND
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containing 2% heat-inactivated fetal bovine serum (FBS) (Gibco)
and 1% Pen/Strep (Gibco). Monocytes were purified by magnetic
bead positive selection (MiltenyiBiotec, City ST). In brief, PBMCs
were incubated with anti-CD14 magnetic MicroBeads for 15
minutes on ice, washed to remove excessive beads, then loaded
onto a MACS column and placed in a magnetic field. CD14+
enriched cells were collected using the appropriate buffer provided
by the manufacturer. The median purity of the CD14+ cells was
91.9% (min: 76.9%; max: 98.7%) by multi-parameter flow
cytometry on every fifth sample for the first 42 cases. Cells were
frozen in 10% DMSO and shipped in batches to the U.S. for the
HIV DNA quantification.
HIV DNA Quantification
We quantified HIV DNA using the QIAamp DNA Micro
Extraction kit (Qiagen, Valencia, CA) using the ND-1000
spectrophotometer (NanoDrop Technologies; Wilmington, DE)
as previously described. [19] Briefly, we used multiplex real-time
PCR with HIV gag and b-globin primer pairs to amplify respective
regions with VIC-labeled HIV gag and FAM-labeled b-globin
probes. Using standard reference plasmids with one copy of the b-
globin housekeeping gene and one copy of the HIV gag gene and
appropriate positive/negative controls, samples were run in
triplicate on StepOnePlus Real-Time PCR System and analyzed
using the SDS 2.3 software (Applied Biosystems, Foster City, CA).
The copy numbers of each sample gene were analyzed against the
standard curves to determine HIV DNA copy number per 106
cells.
Plasma and CSF Cytokines
MCP-1 and IL-6 were quantified in triplicate as part of a
custom multiplex ELISA array according to the manufacturer’s
protocol (Quansys Biosciences, Logan UT). Data were captured
on the Odyssey infrared imaging system (Li-Cor Biosciences,
Lincoln, NE) and analyzed using Quansys Q-view Plus software
(Quansys Biosciences). Single-analyte ELISA was performed in
duplicate to detect levels of neopterin (GenWay Biotech, San
Diego CA) and analyzed using SoftMax Pro (Molecular Devices,
Sunnyvale CA).
Brain MRS
Subjects underwent axial 3D T1-weighted spoiled gradient echo
MRI (TE = 7 ms, TR = 11.2 ms, flip angle = 25u, 1 mm resolu-
tion) on the same GE Signa HDx 1.5T scanner (GE Healthcare,
software v12-M4) with 8-channel head coil and a standard body
coil. Single voxel MRS was acquired by double spin echo data
acquisition (PROBE-P, TE = 35 ms, TR = 1.5 s) at four locations:
left frontal white matter (FWM, 8cc), midline frontal grey matter
(FGM, 8cc), occipital grey matter (OGM, 8cc), and basal ganglia
(BG, 8cc) (Figure 1). Sixteen unsuppressed water free induction
decays (FIDs) and 128 water suppressed FIDs were acquired for all
locations, with 192 water suppressed FIDs acquired at BG. We
measured N-acetyl aspartate (NAA), choline (Cho), myoinositol
(MI), glutamate+glutamine (Glx), and creatine (Cr). To ensure
scanner stability, short echo-time (TE = 35 ms) single voxel MRS
was obtained using a standard spectroscopy phantom (GE
Healthcare) after each scan. [20].
Data were securely transferred and processed by one author
(NS) using the time domain linear combination fitting software,
LCModel (version 6.2, http://s-provencher.com/pages/lcmodel.
shtml). Time domain MRS data from each of the 8-channel
phased array head coils were combined using unsuppressed water
FIDs from each coil as scaling factor. [21] The FIDs were
processed without spectral line broadening for fitting. Fittings were
performed between 4.0–0.5 ppm, using a reference basis set
acquired using the same data acquisition. All reference solutions
were adjusted to pH 7.2 with 0.1 M NaOH. Metabolite
quantification for NAA, Cr, Cho, MI, and Glx was included only
if the signal to noise ratio was .4 and the percent standard
deviations were ,20%. [22].
Statistical Analysis
We used Kruskal-Wallis and student t-tests to compare HAND
and non-HAND groups, and logistic regression to examine the
association between HAND and clinical variables. We constructed
a receiver operator characteristics (ROC) curve to determine the
optimal CD14+ HIV DNA cutoff for detecting HAND, and
evaluated the performance of the classifier using the area under
the curve. Multiple regression models were used to relate
predictors to the NPZglobal score. We also evaluated the
association between HIV DNA and the three cytokines of interest
(MCP-1, neopterin, and IL-6). All values were log transformed
prior to inclusion in our models. Predictors included log10
transformed HIV DNA copy number, plasma HIV RNA, and
cytokine measures. For MRS analyses, we hypothesized finding
higher MI and lower NAA associated with HIV DNA, but we also
examined Cho and Glx. Each voxel was analyzed independently
by regressing HIV DNA copy number on each metabolite
separately with age, gender, and creatine included in the models.
Results
All subjects were enrolled between March 2009 and December
2011. Among these, 35 (57%) were female and the mean (SD) age
was 34.7 (6.9) years. At consensus conference, 28 subjects met
criteria for HAND: 14 with ANI, 8 with MND, and 6 with HAD.
The HAND and non-HAND groups did not differ in main
demographic and clinical variables (Table 1).
HIV DNA and Cognition
The median (IQR) HIV DNA copy number per 106 CD14+
cells was 27 (18, 54), 68 (46, 158), 109 (66, 213), and 138 (114, 265)
for NL, ANI, MND and HAD, respectively (p,0.001, Figure 2).
The CD14+ HIV DNA reservoir burden was associated with
HAND (ANI+MND+HAD) in both univariate (OR = 14.9,
p,0.001) and multiple logistic models (OR = 14.5, p= 0.001)
adjustment for concurrent CD4+ T-lymphocyte count and plasma
HIV RNA (Table 2). For given CD4+ T-lymphocyte and HIV
RNA levels, the odds of observing HAND increased by 14.5 (95%
CI 3.00–69.7) per one log-value increase in HIV DNA copy
number (10-fold increase in raw scale). We identified a moderate
discriminative power as a diagnostic test for HAND (AUC = 0.79,
Figure 3). When an optimal point, determined by Youden’s
index, of 45 copies of HIV DNA per 106 CD14+ cells is used, this
model provided a sensitivity of 86% and a specificity of 70%. In
contrast, no correlation with cognition was observed for HIV
DNA measured from the full PBMC pool prior to enriching for
CD14+ cells. The median PBMC HIV DNA (IQR) was 943
(417,2613), 1677 (243,2458), 1110 (422,4539), and 1037
(435,2673) for NL, ANI, MND and HAD, respectively (p= 0.99)
and 943 vs.1163 copies per 106 cells, for non-HAND vs. HAND,
respectively (p= 0.87). CD14+ HIV DNA was not associated with
plasma HIV RNA.
The association between CD14+ HIV DNA and consensus
diagnosis was similarly reflected in the summary neuropsycholog-
ical testing score. Simple linear regression models revealed that
both HIV DNA (r2 = 0.064, p= 0.049) and plasma HIV RNA
(r2 = 0.089, p = 0.020) were associated with NPZglobal. When both
HIV DNA Reservoir Size and Risk for HAND
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measures were included in a multiple regression model (adj.
r2 = 0.091), the effect of each was attenuated (p= 0.105 and
p= 0.041 for HIV DNA and HIV RNA, respectively). Neither
CSF HIV RNA nor CD4+ T-lymphocyte count was associated
with NPZglobal. We found no association between PBMC HIV
DNA and the NPZglobal.
HIV DNA and MRS
We identified an association between CD14+ HIV DNA and
the two primary hypothesized metabolites, NAA and MI. The
association with MI was noted in BG [point estimate (SD): 0.0224
(0.009), p= 0.0174], FGM [point estimate (SD): 0.0160 (0.006),
p= 0.0116], and OGM [point estimate (SD): 0.015 (0.007),
p= 0.033] (see values in Table S1). Similarly, the association
with NAA was noted in the BG [point estimate (SD): 20.01449
(0.007), p= 0.031], FGM [point estimate (SD): 20.015 (0.006),
p= 0.0153], and OGM [point estimate (SD): 20.0114 (0.005),
p= 0.0260] but also noted in FWM [point estimate (SD): 0.017
(0.004), p= 0.000320]. We did not identify associations between
CD14+ HIV DNA and Cho or Glx at any voxel. Eight voxel-
metabolite data points (0.6%) were visually identified as outliers
despite spectra of acceptable quality. To ensure that our findings
were not driven by these outliers, we repeated the analysis
excluding these data points and lost significance at the p= 0.05
level for both MI and NAA in the basal ganglia (p= 0.09074,
p= 0.15652, respectively). Findings in other voxels did not change
appreciably.
Associations to Plasma and CSF Cytokines
Among the three cytokines of interest, HIV DNA was only
associated with neopterin. This was identified in plasma
(r2 = 0.066, p= 0047) and CSF (r2 = 0.123, p= 0.023). In models
adjusted for plasma HIV RNA and CD4+ T-lymphocyte count,
these associations remained significant (r2 = 0.430, p= 0.014 and
r2 = 0.328, p= 0.012 for plasma and CSF neopterin, respectively,
Figure 4). Plasma IL-6 was detected in only 11% of cases, which
we felt was insufficient to subject to statistical testing. HIV DNA
was not associated with plasma MCP-1 (p= 0.805). Neither CSF
IL-6 (p= 0.711) nor CSF MCP-1 (p= 0.679) were associated with
HIV DNA.
Discussion
This paper summarizes the primary findings from a prospective
blinded study to determine if higher intracellular HIV DNA
reservoir size increases the risk for HAND and whether it is
associated with CSF inflammation and MRS abnormalities. When
PBMCs are purified to be enriched with monocytes (CD14+), we
Figure 1. MRS voxel locations (representative examples). 1. Occipital grey matter, 2. Frontal grey matter, 3. Frontal white matter, 4. Basal
ganglia.
doi:10.1371/journal.pone.0070164.g001
Table 1. Clinical characteristic of enrollees. For CSF, n= 22 for
NL and 21 for HAND groups.
NL (n = 33) HAND (n = 28) p-value
Age, mean (SD) years 35.3 (6.5) 34.0 (7.4) 0.373
Education, mean (SD) years 10.9 (4.4) 11.4 (5.0) 0.595
Gender, n (%) female 18 (54) 17 (60) 0.627
CD4 T-lymphocyte count,
median (IQR)
255 (114,363) 213 (121,280) 0.238
Plasma viral load, median log10
(SD)
4.77 (3.95, 5.13) 4.96 (4.65, 5.59) 0.081
CSF viral load, median log10
(SD, n)
4.07 (3.34, 4.69) 3.97 (3.53, 4.75) 0.7893
doi:10.1371/journal.pone.0070164.t001
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identified associations between the magnitude of this reservoir and
HAND, poorer neuropsychological test performance, neuronal
injury (reduced NAA), glial dysfunction (increased MI), and CSF
immune activation (higher neopterin). Our methodology did not
determine if these intracellular reservoirs are actively producing
viral RNA. We designed our quantification strategy to increase the
likelihood of isolating integrated viral DNA by excluding small
fragments, such as those potentially forming non-integrated and
non-active circular HIV DNA. Small amounts of lymphocyte
contamination occurred with our CD14+ magnetic bead column
Figure 2. CD14+ HIV DNA and cognition. HIV DNA and HAND (first two bars, p= 0.0004) and across diagnostic groups (last four bars, p,0.001).
All HAND=ANI+MND+HAD.
doi:10.1371/journal.pone.0070164.g002
Figure 3. Receiver operating characteristic (ROC) curve for level CD14+ HIV DNA identifying HAND. ROC of CD14+ HIV DNA
only = 0.7922, ROC adjusting for CD4+ T-lymphocyte and plasma HIV RNA: 0.8247.
doi:10.1371/journal.pone.0070164.g003
HIV DNA Reservoir Size and Risk for HAND
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separation; however, the lack of association with PBMC HIV
DNA increases the likelihood that the monocyte fraction drives the
associations we found. Our findings suggest that the eradication of
HAND may require approaches beyond standard cART since
these reservoirs remain present despite treatment. [23] The impact
of intracellular HIV DNA was independent of HIV RNA in
plasma or CSF and of CD4+ T-lymphocyte count; however, over-
lapping mechanisms likely exist since the magnitude of our
findings is attenuated in multivariate models. This is particularly
true for the cytokine analyses, which appear to be driven in large
part by HIV RNA (data not shown).
We did not identify links to HIV DNA measured in PBMCs,
although these associations have been noted in previous small
studies. [4,5] This is unfortunate, since isolating CD14+ cells
requires added resources and time and may not be available
internationally. This finding, however, is not surprising given
existing theories that monocytes traffic virus to the CNS. [24]
Logically, the large presence of lymphocytes in the PBMC pool
would dilute the effect of monocyte HIV DNA such that
associations are stronger when enriching for monocytes.
Use of biomarker evidence for CNS injury strengthens this
work. As hypothesized, CD14+ HIV DNA was associated with
glial dysfunction (increased MI) and neuronal injury (decreased
NAA). The loss of significance in the basal ganglia when excluding
outliers suggests the finding at this location was unstable and may
be due to challenges in voxel shimming at this site; however no
changes were noted in other regions. We did not identify
associations between HIV DNA and Cho, suggestive that HIV
DNA-related injury is likely due to chronic low level immune
activation rather than a robust infiltrative cellular process. This is
not surprising since the actual CD14+ reservoirs are small – the
largest amount measured in this study was 559 copies/106 cells.
We measured neopterin, MCP-1, and IL-6 due to known linkage
to monocyte pathogenesis, but only neopterin was linked to HIV
DNA. The lack of association between HIV DNA and MCP-1 was
unanticipated, since MCP-1 has been linked to dementia. [25].
Our work extends existing paradigms by implicating intracel-
lular reservoirs in HAND pathogenesis. In this study, all
participants were naı¨ve to cART, yet we still identified a
relationship that was independent of plasma or CSF viral load.
These reservoirs are not universally suppressed with cART and
past correlative work from our group notes associations to
cognitive impairment when intracellular suppression is incomplete.
[1,5,19,26,27,28] This work should encourage further research
into the monocyte reservoir as a therapeutic target for HAND. In
a past study of treated patients with suppressed HIV RNA, a novel
score of antiretroviral effectiveness in monocytes was higher in
subjects without HAND. [8] Thus, the presumed concentrations of
antiretrovirals in the brain, as measured by the CPE, incompletely
informs the effectiveness of cART on HAND.
Another strength of this work is the availability of normative
data and the use of consensus diagnostic conference for HAND.
[17] The population was selected to be cART-naı¨ve but with
CD4+ T-lymphocyte counts indicating a need to start cART
(,350 cells), though several cases had higher levels at enrollment.
Our findings can only inform a similar population, but a
longitudinal follow-up of this group is underway. The predomi-
nant HIV subtype in Bangkok is the circulating recombinant form
(CRF) AE_01, but our past work notes similar characteristics of
HAND in CRF AE_01 compared to other clades, and we have
previously identified associations between HIV DNA and cogni-
tion in clade B infected subjects. [5,15,29] The sample size, while
small, was planned to have sufficient power based on past data.
Nevertheless, the effect sizes noted in comparison to the
NPZglobal score appeared substantially smaller than those seen
in past studies by our group. [4] These past studies enrolled
participants with chronic, treated HIV infection, a suggestive
finding that more profound effects may be identified in the setting
Table 2. Regression analysis of the association of CD14+ HIV
DNA and HAND.
Univariate Logistic Regression Odds Ratio p-value
log10CD14
+ HIV DNA 8.29 0.002
Multivariate Logistic Regression Odds Ratio p-value
log10CD14
+ HIV DNA 14.47 0.001
log10HIV RNA 2.04 0.167
CD4+ T-lymphocyte count 1.00 0.924
doi:10.1371/journal.pone.0070164.t002
Figure 4. Plasma CD14+ HIV DNA and plasma neopterin (left, p=0.0473, adjusted r2 =0.0662) and CSF neopterin (right, p=0.023,
adjusted r2 =0.123) by univariate regression.
doi:10.1371/journal.pone.0070164.g004
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of cART. It is possible that the effects of low CD4+ T-lymphocyte
count and high plasma HIV RNA mask the impact of HIV DNA
among untreated cases.
In summary, the level of HIV DNA in circulating cells with
CD14+ phenotype is related to risk for HAND in treatment-naı¨ve
Thai subjects with moderate to advanced immune suppression.
This marker also correlates to MRS markers of brain injury and,
nominally, to neopterin levels. New efforts are needed to
understand the mechanisms by which intracellular HIV DNA
levels contribute to neuronal injury.
Supporting Information
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